<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250247</url>
  </required_header>
  <id_info>
    <org_study_id>1UG3HL138325-01</org_study_id>
    <nct_id>NCT03250247</nct_id>
  </id_info>
  <brief_title>Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)</brief_title>
  <acronym>C-TRACT</acronym>
  <official_title>Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Clinical Oncology Group (OCOG) - McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VasCore - Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mid America Heart Institute - St. Luke's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of image-guided, endovascular therapy
      (EVT) is an effective strategy with which to reduce Post Thrombotic Syndrome (PTS) disease
      severity and improve quality of life in patients with established disabling iliac-obstructive
      post thrombotic syndrome (DIO-PTS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rationale for performing the C-TRACT Trial is based upon:

        1. the debilitating life impact of DIO-PTS upon patients, as cited in the U.S. Surgeon
           General's 2008 Call to Action on DVT (95);

        2. the inability of existing therapies to prevent or alleviate most cases of DIO-PTS;

        3. the role of iliac vein obstruction and saphenous reflux in causing the severe
           manifestations of DIO-PTS;

        4. the ability of stent placement and endovenous ablation to eliminate obstruction and
           reflux, respectively, to reduce PTS severity, and to improve QOL in preliminary studies;

        5. the risks, costs, and uncertainties of this novel but invasive strategy;

        6. the lack of consensus on whether EVT should be used for DIO-PTS;

        7. the motivation of our established investigator team to answer this critical clinical
           question.

      We will determine if EVT should be routinely used to treat DIO-PTS. If so, this finding will
      fundamentally change DIO-PTS practice towards more frequent use of EVT. If EVT proves
      ineffective or unsafe, this finding will reduce or eliminate the use of potentially risky and
      expensive procedures.

      374 subjects with established DIO-PTS will be randomized in a 1:1 ratio to either EVT or
      No-EVT treatment groups. All participants will receive standard PTS therapy. Subjects will be
      enrolled over approximately 36 months in 20-40 U.S. Clinical Centers, and followed for 24
      months. The study will take approximately 6 years to complete.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an NIH-funded, Phase III, multicenter, randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Clinical assessments for PTS will be obtained at baseline (pre-randomization) and at the 6, 12, 18 and 24-month follow-up visits. Examining clinicians will complete PTS training to ensure accuracy across all Clinical Centers. The examiners for PTS must be blinded to the subjects' treatment allocation. Subjects will be reminded not reveal to clinic staff which therapy they received (EVT or No-EVT). Subjects should be examined in the afternoon (the later the better) to allow the symptoms and signs of PTS to manifest. The assessment is performed as follows:
The subject should be asked to rate the 5 symptoms on the Villalta PTS scale for each leg, record his/her ratings on the CRF.
The subject's legs should be unclothed and he/she should be seated facing the blinded clinician (nurse or physician).The 5 signs of PTS and VCSS measures will be recorded by the blinded clinician. Leg ulcers (if present) will be assessed and measured.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PTS Severity</measure>
    <time_frame>over 6 months follow-up</time_frame>
    <description>374 patients with moderate to severe post thrombotic syndrome (PTS) and iliac vein obstruction will receive optimal PTS therapy. 50% of those patients will also receive endovenous therapy; modified antithrombotic therapy, including anti-platelet agent, iliac vein stenting, and endovenous ablation of refluxing saphenous veins if indicated. At 6 months post-randomization, venous clinical severity scores (VCSS) will be obtained and PTS severity will be evaluated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Stasis</condition>
  <condition>Venous Insufficiency</condition>
  <condition>Venous Leg Ulcer</condition>
  <condition>Venous Reflux</condition>
  <condition>Post Thrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Endovascular Therapy - Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.
Subjects randomized to EVT will receive the following:
imaging-guided iliac vein stent placement, and
endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.
optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Endovascular Therapy - Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All subjects will receive optimal PTS care as noted above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stents</intervention_name>
    <description>US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.
Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.
The use of devices &gt; 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.
Balloon angioplasty of inflow veins.
After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.
Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation.</description>
    <arm_group_label>Endovascular Therapy - Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Disabling (moderate-to-severe) PTS, defined by a) presence of chronic venous disease &gt;
             3 months duration in a leg with history of DVT; and b) either a Venous Clinical
             Severity Score (VCSS) &gt; 8 or a Villalta PTS Scale score &gt; 10 or an open venous ulcer);
             and

          2. Ipsilateral iliac vein obstruction (occlusion or &gt; 50% diameter stenosis), documented
             by traditional venogram, CT venogram, MR venogram, or intravascular ultrasound
             (IVUS)).

        Exclusion Criteria:

          1. Age less than 18 years

          2. Acute proximal DVT episode within the last 3 months

          3. Lack of suitable inflow into the common femoral vein per the treating physician

          4. Documented obstruction (occlusion or &gt; 50% diameter stenosis) of an IVC filter

          5. Chronic arterial limb ischemia (ankle-brachial index &lt; 0.5)

          6. Presence of open venous ulcer &gt; 50 cm2 area, or suspicion for active ulcer infection

          7. Inability to tolerate endovascular procedure due to acute illness, or general health

          8. Severe allergy to iodinated contrast refractory to steroid premedication

          9. Known allergy to stent or catheter components

         10. Hemoglobin &lt; 8.0 g/dl, uncorrectable INR &gt; 3.5, or platelet count &lt; 50,000/ml

         11. Severe renal impairment (estimated GFR &lt; 30 ml/min)

         12. Disseminated intravascular coagulation or other major bleeding diathesis

         13. Pregnancy (positive pregnancy test)

         14. Life-expectancy &lt; 6 months or chronically non-ambulatory for reasons other than PTS

         15. Inability to provide informed consent or to comply with study assessments Note -
             patients who initially meet an exclusion criterion can be re-screened at a later date,
             and may be enrolled if all eligibility criteria are met at that time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Vedantham, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Coordinating Center at Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Oliver, RN, BSN, MS</last_name>
    <phone>314-747-8951</phone>
    <email>olivera@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Thompson, MA</last_name>
    <phone>314-747-2379</phone>
    <email>thompsona@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Passman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephen Kee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Vascular Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mahmood Razavi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Leung, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristie Kennedy, MA</last_name>
      <phone>312-695-4023</phone>
      <email>kristie.kennedy@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kush Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Eskandari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karlyn Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramona Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brady Stein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsey Kalhagen, MMS, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMITA Health Adventist</name>
      <address>
        <city>LaGrange</city>
        <state>Illinois</state>
        <zip>60439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Sichlau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central DuPage</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joseph Schneider, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mel Sharafuddin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Oliver, RN, BSN, MS</last_name>
      <phone>314-747-8951</phone>
      <email>olivera@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Thompson, MA</last_name>
      <phone>314-747-2379</phone>
      <email>thompsona@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suresh Vedantham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naganathan Mani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Miriovsky</last_name>
      <phone>402-219-7936</phone>
      <email>mmiriovsky@stez.org</email>
    </contact>
    <contact_backup>
      <last_name>Julie Potter</last_name>
      <phone>402-890-1019</phone>
      <email>jpotter@stez.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Vander Woude, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Razdan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Braun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Voigt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalaish Masolpuruia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Akhilesh Sista, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian-Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ronald Winokur, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Staten Island Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan Schor, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonios Gasparis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Marston, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jobst Vascular Institute</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zakaria Assi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Suman Rathbun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Kaufman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Deepak Sudheendra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Riyaz Bashir, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Hager, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ezana Azene, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Hohenwalter, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Raju S. Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein compression lesions in chronic venous disease. J Vasc Interv Radiol. 2012 Apr;23(4):502-3. doi: 10.1016/j.jvir.2012.01.068.</citation>
    <PMID>22464715</PMID>
  </results_reference>
  <results_reference>
    <citation>Yin M, Shi H, Ye K, Lu X, Li W, Huang X, Lu M, Jiang M. Clinical Assessment of Endovascular Stenting Compared with Compression Therapy Alone in Post-thrombotic Patients with Iliofemoral Obstruction. Eur J Vasc Endovasc Surg. 2015 Jul;50(1):101-7. doi: 10.1016/j.ejvs.2015.03.029. Epub 2015 Apr 25.</citation>
    <PMID>25920630</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss RA, Weiss MA, Eimpunth S, Wheeler S, Udompunturak S, Beasley KL. Comparative outcomes of different endovenous thermal ablation systems on great and small saphenous vein insufficiency: Long-term results. Lasers Surg Med. 2015 Feb;47(2):156-60. doi: 10.1002/lsm.22335. Epub 2015 Feb 24.</citation>
    <PMID>25711984</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>superficial venous reflux</keyword>
  <keyword>blood clot</keyword>
  <keyword>post thrombotic syndrome</keyword>
  <keyword>iliac vein obstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

